Allergic contact dermatitis due to the β-blocker befunolol in eyedrops, with cross-sensitivity to carteolol

Nino, Massimiliano; Suppa, Francesco; Ayala, Fabrizio; Balato, Nicola

doi:10.1034/j.1600-0536.2001.440609-4.x

Cited by 12 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allergic contact dermatitis caused by β-blockers in eyedrops used for the treatment of glaucoma is a known entity, and, in several cases, different patterns of concomitant/subsequent contact dermatitis have been observed (15). However, three reports concerned reactions to β-blockers that had never been used by the patient, indicating true cross-reactivity (14,16,17). The patient reported here had come into contact with all of the tested β-blockers; hence, no statement can be made in this regard.…”

Section: Discussionmentioning

confidence: 99%

Occupational airborne contact dermatitis from benzodiazepines and other drugs

Swinnen

Ghys

Kerre³

et al. 2013

Contact Dermatitis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Occupational airborne contact dermatitis from benzodiazepines and other drugs

Swinnen

Ghys

Kerre³

et al. 2013

Contact Dermatitis

View full text Add to dashboard Cite

show abstract

“…There have been few reports of follicular conjunctivitis and contact dermatitis several months after beta-blocker therapy. 9,10 Recently, Delaney et al 11 reported periorbital dermatitis as a late side effect of topical dorzolamide. In the study by Delaney et al, periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing topical dorzolamide.…”

Section: Discussionmentioning

confidence: 99%

Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population

Bhatt¹,

Whittaker²,

Appaswamy³

et al. 2004

Eye

View full text Add to dashboard Cite

Aim To identify the relative incidence and profile of adverse drug reaction (ADR) to various topical ocular hypotensives in a hospital setting. Methods All the patients presenting in outpatients clinic and accident and emergency with an ADR to topical hypotensive agent from August 2000 to January 2001 were included in the study. Details regarding the type date of commencing the treatment, the date of developing ADR, time to resolution of the ADR were noted. Results Over the period of 6 months, 66 patients presented with 73 ADRs. Brimonidine was the most frequent offending agent. In total, 23 (34.8%) presented with ADR after being commenced on treatment for more than 12 months. In all, 16 (24%) patients had IOP421 on presentation, eight (12%) patients underwent filtration surgery following the development of ADR. Conclusion Adverse drug reaction to ocular hypotensive agents is not uncommon and can have a major impact on glaucoma management. Delayed presentation and association with raised intraocular pressure presentation emphasise the need for effective patient education to encourage prompt reporting of ADR.

show abstract

“…Cross-sensitization between bufenolol and carteolol has also been reported. 9,10 The similar chemical structures of beta-blockers has been proposed as the mechanism for these crossreactions. Difficulties with obtaining positive results with mydriatics have also been described.…”

Section: Patch Testingmentioning

confidence: 99%